Skip to content

SRTA SRTA Warrants And Rights Outstanding

Warrants And Rights Outstanding at other companies

Kestra Medical Technologies, Ltd. Common Stock logo
Kestra Medical Technologies, Ltd. Common StockKMTS
$1.75M

Other financials

Income statement

See full
Revenue$67.4M+87.4%
Gross profit$14.1M+100%
Operating income-$3.0M+47.7%
Net income$2.2M+162%
EPS (diluted)$0.03+175%

Balance sheet

See full
Cash & equivalents$59.0M+65.3%
Total debt$4.5M-50.7%
Total equity$285.7M+30.0%
Total assets$327.6M+30.8%

Cash flow

See full
Operating cash flow$3.9M+1,679%
CapEx$5.2M+98.1%
Free cash flow-$1.3M+54.8%

Valuation

See full
Market cap$463.78M+24.0%
Enterprise value$409.26M
P/E8.9×
P/S1.8×

Profitability

See full
Gross margin21.7%+1.3pp
Operating margin-7.8%-2.8pp
Net margin21%+13.6pp
FCF margin-22.4%+1,712pp

Returns & leverage

See full
Return on equity15.6%+10.0pp
Debt / equity0.0×
Current ratio5.9×-1.0×

Where this comes from

Reported directly by SRTA in its filing.

Tagged under the XBRL concept us-gaap:WarrantsAndRightsOutstanding.

The official record: SRTA’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about SRTA's warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SRTA's warrants and rights outstanding?
SRTA (SRTA) reported warrants and rights outstanding of $71K in Q1 2026.
How has SRTA's warrants and rights outstanding changed year-over-year?
SRTA's warrants and rights outstanding decreased by 97.7% year-over-year, from $3.06M to $71K.
What is the long-term trend for SRTA's warrants and rights outstanding?
Over 4 years (2021 to 2025), SRTA's warrants and rights outstanding has grown at a -53.0% compound annual growth rate (CAGR), from $31.31M to $1.53M.
What does warrants and rights outstanding mean?
This metric represents the total number of derivative instruments, such as warrants or stock rights, that grant holders the option to purchase common shares at a specified price. It serves as a measure of potential future equity dilution that could impact existing shareholders' ownership percentages and earnings per share. Monitoring this figure is essential for assessing the company's long-term capital structure and the potential impact of future share issuances.